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With the significant advancement of high-throughput technologies and diagnostic techniques throughout the past
decades, molecular underpinnings of many disorders have been identified. However, translation of patient-specific
molecular mechanisms into tailored clinical applications remains a challenging task, which requires integration of
multi-dimensional molecular and clinical data into patient-centric models. This task becomes even more challenging
when dealing with complex diseases such as neurodegenerative disorders. Integrative disease modeling is an emerging
knowledge-based paradigm in translational research that exploits the power of computational methods to collect,
store, integrate, model and interpret accumulated disease information across different biological scales from molecules
to phenotypes. We argue that integrative disease modeling will be an indispensable part of any P4 medicine research
and development in the near future and that it supports the shift from descriptive to causal mechanistic diagnosis and
treatment of complex diseases. For each ‘P’ in predictive, preventive, personalized and participatory (P4) medicine, we
demonstrate how integrative disease modeling can contribute to addressing the real-world issues in development of
new predictive, preventive, personalized and participatory measures. With the increasing recognition that application of
integrative systems modeling is the key to all activities in P4 medicine, we envision that translational bioinformatics in
general and integrative modeling in particular will continue to open up new avenues of scientific research for current
challenges in P4 medicine.
Keywords: Disease modeling, Translational bioinformatics, Integrative modeling, P4 medicineReview
Post-genomic era and P4 medicine
Mendel's studies of inheritance patterns laid the foundation
for our current understanding of monogenic or single-gene
diseases in human. The laws of Mendelian inheritance,
however, could not explain the polygenic or multifactorial
inheritance of complex diseases (sporadic vs. familial inher-
itance). Complex diseases such as cancer or Alzheimer's
disease (AD) represent highly heterogeneous clinical
states, which reflect combined effects of various genes
and their interaction with environmental factors. Analysis
and annotation of genomic information has been the
main focus of research in the recent past. Since the* Correspondence: erfan.younesi@scai.fraunhofer.de
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article, unless otherwise stated.publication of the Human Genome Project on 26 June
2000, tremendous progress has been made in whole
genome sequencing, analysis and interpretation. This
progress is reflected in the increasing number of diseases
for which genetic testing is available, according to the
GeneTests database [1] (Figure 1).
Despite the increasing availability of genetic tests
offered by medical laboratories, a fundamental question
remains unanswered: how effectively can such molecular
data sets be translated into clinical applications, ideally at
the point of care, while compatible with patient-centric
view of personalized medicine? Although recent efforts
such as sequencing human exomes [2], 1000 Genomes
Project [3] and Personal Genome Project [4] have been
dedicated to characterizing the vast majority of common
single-nucleotide polymorphisms (SNPs) and structural
variants across the genome, they only provide a one-
dimensional view of genome function. Besides, with thee BioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 The rise of genome-based diagnostic applications. The number of genetic tests for diagnosis of different disease indications -
offered by medical laboratories worldwide - has been growing since 1993.
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DNA sequencers, gene expression microarrays and
mass spectrometry, other forms of high-dimensional
molecular data have emerged that need to be analyzed
and used for more accurate diagnosis and treatment
prescription.
The realization of P4 medicine promises relies on the
ability to manage and integrate different heterogeneous
data types across multiple scales from molecular data sets
to clinical information and medical history of patients.
Handling patients' data and its exchange amongst health-
care information systems has been the focus of informatics
endeavors in the realm of personalized medicine [5].
For example, CDISC (Clinical Data Interchange Standards
Consortium) brings together leading global biotechnology
and pharmaceutical development companies as well as
government institutions, academic research centers and
other non-profit organizations to develop and support
global, platform-independent data standards that enable
interoperability of clinical data amongst information
systems [6]. Although standardization of data storage
and representation is necessary for the future of P4
medicine but it is certainly not enough. The main chal-
lenge to be addressed here by translational bioinformatics
is the problem of linking omics molecular data and
affected biological pathways to clinical readouts and
epidemiological background of patients with complex
diseases. Integration, analysis and interpretation of such
heterogeneous data types in the context of complex
molecular systems requires an integrative approach to
studying systems of biological components, referred to
as systems biology. In the post-genomic era, therefore,
the greatest challenge is to determine how heteroge-
neous ‘-omics’ data can be integrated into a coherentholistic model that can explain the disease phenotype
in a personalized way. The goal of systems approaches
is to decipher the complexity of diseases by integrating
all types of heterogeneous biological information into
predictive and actionable models (Figure 2). Such models
will be central to the premises underlying P4 medicine
because they help investigators bridge the ‘translational
gap’ between basic and clinical research more efficiently.
Following the recommendations of the EPMA white
paper on developing integrative medical approaches [7],
we review the current trend in systems modeling and its
application to the P4 paradigm. Next, we address the four
Ps individually, i.e. predictive, preventive, personalized
and participatory, in the context of translational disease
modeling and provide scenarios for each case using the
latest developments in this area. Finally, we conclude
the review with a summary on the emerging implications
of integrative disease modeling in P4 medicine.
Shifting from genome-based to network-based views of
human disease
With the paradigm shift in the post-genomic era from
single-dimension biological data to multiple dimensions of
heterogeneous data, the concept of personalized medicine,
which originally defined on the basis of SNPs, is now
undergoing a revolutionary change. It is increasingly
recognized that analysis of SNPs in isolation does not
lead to a complete understanding of complex disease
processes and - as a consequence - heterogeneous data
must be analyzed and interpreted in an integrated fashion.
Systems biology analyses have led to the emergence of
new approaches, which take advantage of a network-
based integrative view on different biological components
involved in pathogenesis of complex diseases rather than a
Figure 2 Disease-specific models at the center of data integration. Different data types across multiple biological scales can be aggregated
and integrated into an integrative mechanistic model.
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For example, genome-wide association studies (GWAS)
have been extensively used to unravel complex associations
between genes and diseases at the level of SNPs but
they do not provide sufficient context for understanding
the complexity of pathological dysregulation involved
in the initiation and progression of complex diseases.
The knowledge provided by GWAS has a number of
limitations that restricts its application, when used slone:
the affected genes are difficult to definitively identify and
localize, the alteration of gene function by identified SNPs
in the context of disease cannot be immediately elucidated
and it often remains unknown which particular pathways
might be modulated by the SNPs that were found [8-10].
Instead, molecular networks that represent molecular
states of the perturbed biological system underlyingFigure 3 The cycle of systems modeling.disease (also known as disease maps) provide a suitable
framework for transitioning from ‘descriptive’ to ‘mech-
anistic’ mode by linking genetic information to disease
processes and clinical phenotypes. It is within such a
framework that associations amongst biological entities
become apparent and a bigger picture of the disease
mechanism emerges [11]. To this end, construction of
disease-specific molecular maps constitutes the first
step towards integrative disease modeling: for example,
a computationally tractable interaction map of Parkinson's
disease that integrates pathways implicated in Parkinson's
pathogenesis has been recently constructed and made
openly accessible [12]. However, disease molecular maps
only serve as a backbone for the addition of other comple-
mentary data from multiple biological scales so that
such maps, enriched with genetic variation information,
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hypotheses from those models, which can be further
validated in the wet lab (Figure 3).
Model-driven approach to integrating biomedical
knowledge and data
In parallel to the unprecedented growth of experimental
data produced by high-throughput technologies, the rate
of published knowledge through the biomedical literature
has been constantly increasing. Biomedical literature
including scientific publications and health records
contain valuable information in free-form densely written
text. When extracted and converted from unstructured
to structured form, literature-derived information can
complement data-driven approaches by refining hypoth-
eses generated from high-throughput data sets. Such
information helps to distinguish signal from noise when
analyzing and interpreting high-throughput data sets
[13]. For example, network models of prior biological
knowledge have been used to measure the amplitude of
perturbation that a given stimulus such as drug treatment
or environmental agent induces in a biological system
through alterations in gene expression; in this way, the
biological impact caused by environmental factors,
toxic substances, or drug treatments can be scored and
compared [14].
Integration of both experiment-derived and literature-
derived information into a single framework has been suc-
cessfully used for analysis and interpretation of biological
mechanisms underlying disease using computationalFigure 4 Model-driven approach to integrating biological data. Propo
into a single disease model, which could represent correlations (left) or caumodels. Usually modeling biological mechanisms can be
driven either by high-throughput experimental data or by
prior knowledge of molecular biology published in the
literature. The former approach, known as ‘data-driven
modeling”, is solely based on the data and no
assumption is made about the underlying mechanisms
[15]. The limitation of the data-driven approach is, how-
ever, the small amount of available quantitative data and
the heterogeneity of such data sets. These limitations can
be largely compensated with the qualitative statements
from the literature [16]. Therefore, the so-called ‘know-
ledge-driven modeling’ approach makes use of systematic-
ally captured expert knowledge, text-mining technologies
and semantic resources such as ontologies to build or
validate biological networks [17].
Based on the complementary nature of these two
modeling approaches, we propose a hybrid approach -
the so-called ‘model-driven approach’ - that combines
both data- and knowledge-driven methods. The models
generated by this approach could represent correlation
or cause and effect, depending on the type of associations
between pairs of variables in the network model (Figure 4).
Correlation network models are routinely built using
high-dimensional data such as protein-protein interactions
or gene expression data by establishing pairwise relations
(i.e. edges) for all variables (i.e. nodes) but they confound
direct and indirect associations (‘is_somehow_related_-
with’) and do not distinguish between cause and effect.
In contrast, causal network models aim at representing
response variables and covariates and, thus, thesed model-driven approach combines biomedical knowledge and data
se and effect (right).
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When relationships between variables represent condi-
tional dependencies (e.g. Given disease symptoms,
compute the probabilities of the presence of various dis-
eases), the model is a Bayesian network, which requires in-
formation on prior distribution. In the absence of such
information, Biological Expression Language (BEL) offers
an alternative. BEL is the state-of-the-art causal network
modeling language that integrates literature-derived
‘cause and effect’ relationships into a data-driven plat-
form and produces casual network models [18].
We have recently developed BEL-based, computer-
processable models representing the physiology of amyloid
beta precursor protein (APP); these models represent
both the normal and the diseased condition. We have
used these models for differential network analysis.
Central role of integrative modeling in the future of P4
medicine: moving beyond genomics
With the increasingly complex relationship between basic
research and clinical application, there is a pressing
need to bridge the translational gap from bench to clinic
using integrative methods. The mission of ‘translational
bioinformatics’ is, therefore, to provide infrastructure
and techniques that enable integrative modeling of the
whole biological system across multiple scales. Since
the objective of P4 medicine is to enable a multitude
of purposes in the frame of individualized healthcare
including predictive modeling, preventive measures and
personalized treatments, a significant amount of personal-
ized data and information should be managed for proper
individualized diagnosis and prognosis. As mentioned
above, integrative modeling approaches provide a suitable
medium for fusion of such data and interpretation of
the information derived from such models. We believe
that integrative modeling approaches become the major
building block of future P4 medicine efforts as their
potential in bridging the translational gap is going to be
increasingly appreciated and we will soon witness the
first examples for model-driven, personalized treatment
optimization.
Application of integrative methods enforces a paradigm
shift from the conventional concept of personalized
medicine - merely based on genetic makeup of patientsFigure 5 Decision support options provided by the integrative diseas
provide support to both basic researchers and clinicians in making decision(SNPs) - to a modern concept that includes SNPs as one
piece of information within a bigger picture amongst other
data types. An outcome of this activity is generation of
various models that can provide decision support for
both researchers and clinicians (Figure 5). For instance,
the integration of brain imaging information from each
patient into a molecular network model that explains
the mode of action of CNS drugs could support clini-
cians in making decisions about diagnostic or prognostic
measures. Similarly, enriched disease models can sup-
port the identification of the optimal drugs for targeted
treatment of individual patients through the so-called
drug-biomarker co-development. Taken together, we envi-
sion that general disease models will be personalized
and tailored to the need of individual patients through
enriching the model with specific patient data.
Contribution of integrative modeling to P4 medicine
The anticipation that integrative modeling lies at the core
of the future P4 medicine raises an important question:
how integrative systems models could contribute to
solving the real-world problems in predictive, preventive,
personalized and participatory areas? In the following, we
review the potential contribution of integrative modeling
to each P and provide a scenario per P to showcase the
applicability of the integrative models to all aspects of
P4 medicine.
Predictive: early diagnosis for the prevention of chronic
degenerative diseases
Given the increasingly crucial role of molecular data
in the clinical management of patients with complex
diseases such as cancer, predictions based on diagnostic
biomarkers are emerging as major players in individual-
ized medicine. Biomarkers are defined as indicators of
normal biological processes, pathogenic processes, or
pharmacological responses to a therapeutic. Diagnostic
biomarkers not only support detection of prodromal
signs but also determine the progression rout of the
disease through indication of stage of the disease or
subclinical manifestation of the disease [19].
Predictive diagnostics are needed for early treatment
of complex diseases such as Alzheimer's disease or
cancer, which present clinical heterogeneity. Conventionale modeling approach. The integrative modeling approach can
s about diagnostic or prognostic measures.
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ameter encounter the danger of low sensitivity to accur-
ately differentiate patients with highly heterogeneous
clinical manifestations. Genome-based molecular fin-
gerprints, including gene expression profiling, have
proven successful in linking genome-level events to clin-
ical metrics but they remain far from the clinical applica-
tion, as they often require invasive sampling and their
measurements suffer from lack of consistency. An alterna-
tive to such a ‘signature-based approach’ would be a
‘multi-panel approach’ by which gene expression informa-
tion is linked to proteomics and pathophysiology of dis-
ease so that many different types of biomolecules (i.e. a
panel of biomarkers) are being associated to pathological
processes [20]. Integrative approaches that make use of
network models as integration platform have shown a
great promise for supporting discovery of highly discern-
ing subsets of molecular biomarkers from the vast com-
binatorial space of molecular candidates [21]. For
instance, the integration of gene expression profiles ob-
tained from primary breast tumors in a protein interaction
network model led to identification of sub-network bio-
markers that represent metastatic tumor progression [22].
Although predictive diagnostics are conventionally rep-
resented by genome-based methods and tests, imaging
markers are emerging as an integral part of medical diag-
nosis, particularly for diagnosis of neurological disorders.
Hence, translating imaging readouts to diagnostic mo-
lecular biomarkers is expected to be extremely valuable.
To this end, we have developed an algorithm that incorpo-
rates the diagnostic knowledge of imaging and potential
protein biomarkers specific to Alzheimer's disease into a
brain-specific protein interaction network [23]. As a result,
three network models representing disease stages were
generated and subjected to pathway analysis (Figure 6).
The results indicated that, in contrast to the widely ac-
cepted amyloid pathway hypothesis, particular pathways
are causally related to the disease mechanism. This was
not appreciated before.Figure 6 Modeling staging mechanism in Alzheimer's disease. Schema
information into stage-specific disease maps.Preventive: reducing the likelihood of disease and disability
The primary goal of preventive measures against complex
diseases is to identify at-risk individuals long before the
development of disease symptoms (for instance, indi-
viduals at risk of developing Alzheimer's disease) so
that preventive treatments can be planned. Accordingly,
preventive biomarkers aim at screening a population and
stratifying individuals at a high risk of developing disease
by measuring the association between their molecular
profile (e.g. gene expression or genetic variation) and
disease phenotype. However, finding efficient preventive
biomarkers is a non-trivial task that requires character-
ization of composition, distribution and function of key
molecules involved in the disease mechanism.
Computational modeling approaches have been used
already to assist the process of stratification biomarker
discovery for cardiovascular diseases [24]. Recently, an
interesting area for application of computational models
to disease prevention is emerging that uses mechanistic
models to reveal interdependencies between the disease
and risk mechanisms (Figure 7). Such interdependencies
are reflected in comorbidities that co-occur with the dis-
ease and increase the disease risk.
In the following, we present a scenario that shows
therapeutic prevention of diabetes can reduce the risk
of developing Alzheimer's disease in at-risk populations.
Epidemiological findings indicate that type II diabetes
mellitus is linked to developing and exacerbating AD
pathology [25,26] so that Alzheimer's has been even
proposed by some authors to be ‘type III diabetes’ [27,28].
Very recently, a 9-year prospective study on 3,069 elderly
adults without dementia demonstrated that patients who
suffered from diabetes had significantly worse cognitive
decline in comparison with those who did not have the
disease, suggesting the contribution of diabetes mellitus
severity to accelerated cognitive impairment [29]. On the
other hand, pharmacological studies provide evidence that
application of anti-diabetes drugs confer protective effects
to demented brains. In mouse models of Alzheimer'stic representation of the proposed workflow for translation of imaging
Figure 7 Deterministic factors involved in shaping the disease phenotype. The disease phenotype is the result of interactions between
causative molecules, environmental factors and disease-modifying molecules.
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din-4 reversed insulin pathology and improved cognition
significantly [30]. In another study, it was shown that the
diabetes drug Liraglutide prevents key neurodegenerative
developments in a mouse model of Alzheimer's disease
[31]. Rosaglitazone, another anti-diabetic agent, also
showed beneficial effects for dementia treatment when
administered at low dose [32]. In spite of such growing
evidence, the molecular mechanism underlying this
protective effect is still unclear and thus, aggregation
and analysis of disparate knowledge on this topic in the
frame of a unified computational model may facilitate the
mission of finding a preventive treatment for Alzheimer's
disease. In this direction, we have recently proposed a
mechanistic model for genomic hormone interactions
underlying dementia, which not only reveals the possible
molecular connections between the insulin signaling
pathway and learning/memory functions but also explains
the preventive mode of action by serendipitous off-target
effects of several approved drugs [33].Figure 8 Stratification of patient population based on disease mechaPersonalized: targeted therapy as an emergent trend in
drug discovery and development
The concept of personalized medicine was first coined
in the context of genetics but its definition has been
extended beyond genomics to the customization of
healthcare measures to individual patients [34]. The ul-
timate goal of personalized medicine is to use integra-
tive data to better target the delivery of healthcare and
treatments to individuals [35]. Therefore, strategies and
methods are required to enable classification of individuals
into subpopulations based on their susceptibility to disease
or response to treatment (Figure 8). Accordingly, success-
ful stratification of individuals is the key to the following
preventive and therapeutic interventions [36].
Prognostic and predictive biomarkers are considered
to be the key contributors to the success of personalized
medicine. Prognostic biomarkers stratify patients under-
going a specific therapy based on the risk of disease
progression whereas predictive (stratification or compan-
ion) biomarkers identify patients who are more likely tonism.
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A major drawback in delivering right pharmacological
treatment to right patients is that the current therapeutic
options are based on the ‘one-size-fits-all’ paradigm and
thus not appropriate for stratification of responders from
non-responders to treatment. Due to this fact and also
because of a couple of other reasons, including the
pressing need for better safety and efficacy indices and
the need to control increasing healthcare expenditures,
a new trend is emerging in pharmaceutical businesses that
shifts from mass therapies towards targeted therapies
based on so-called companion biomarkers [37]. Despite
previous success stories of companion biomarker appli-
cations, a significant gap exists between the R&D ex-
penditure and available clinically validated biomarkers.
Therefore, better understanding of the mode of action of
drugs as well as the alternative pathways that can reduce
therapeutic effects will be crucial to discovery of novel
companion biomarkers.
We have recently reviewed current biomarker-discovery
technologies highlighting challenges and opportunities
for oncology biomarker discovery with the emphasis on
computational integrative modeling approaches as an
emerging trend in biomarker prediction [38]. The overall
trend indicates that there is a move away from correlative
biomarkers towards causative biomarkers. Thus, the aim
of next-generation integrative models is to capture causal
relationships between candidate biomarker and clinical
outcome. A prime example is development of predictive
biomarker content for identification of patients with
ulcerative colitis who could be potential responders to
targeted anti-TNF therapy with Infliximab [39]. Based on
the prior knowledge in the literature, a causal network
model was constructed that describes mechanistic
knowledge underlying ulcerative colitis in the form of
the ‘cause-relationship-effect’ pattern. Next, gene expression
profiles of responders and non-responders were incorpo-
rated into the causal model and a mechanistic strength
value was calculated on the gene expression network
activity signature of TNF signaling for each patient in the
population. The model demonstrated that non-responders
have different TNF signature compared to responders,
which was due to sustained TNF-like downstream signal-
ing in non-responders after treatment with Infliximab,
controlled by alternative upstream controllers.
Participatory: enriching models with patient-centric
information and experiences
In parallel to the concepts of personalized medicine and
targeted therapy, patient-centric medicine is developing
based on patient-oriented research. The aim of patient-
oriented research is to identify the best treatment strategy
guided by disease heterogeneity diagnostics [40]. The
internet has facilitated participation of individual patientsin the healthcare through sharing their experiences in
blogs and other social media. Indeed, online patient
communities represent a true model for participatory
medicine. For instance, PatientsLikeMe [41] is an online
patient community that provides robust methods for
patients to share their experiences on effectiveness of
treatments. Since such virtual environments act as reposi-
tories of self-reported data on the nature of disease,
treatment response and side effects, they have the poten-
tial to be used for refining the existing drug-response
models or optimizing clinical outcomes. For instance,
Wicks et al. (2011) used the self-reported data of 348 ALS
patients - posted on the PatientsLikeMe website - and
based on these reports demonstrated that treatment
with lithium carbonate has not been beneficial for the
patients [42].
Together with blogs and online resources, electronic
health records (EHRs) present valuable sources for inte-
grating patient data into disease models. EHRs have been
used to stratify neuropsychiatric patient cohorts based
on complete phenotypic profiles than the conventional
primary diagnosis [43]. Very recently, we have applied our
Alzheimer's disease ontology (ADO) to 650 AD patients'
health records and demonstrated that four major comor-
bidities reported in these records also link mechanistically
to the pathology of AD [44]. There are emerging initiatives
like the ‘Quantified Self ’ initiative [45], which will lay the
foundation for the concept of virtual patient. The virtual
patient is a model that can be compared (and populated/
parameterized) by individuals. Quantified Self initiative
collects self-tracking tools and applications in one place
and facilitates finding and access to self-recording/self-
reporting application softwares.
In summary, the integration of medical data from par-
ticipating patients into disease models is imperative if
these models are to be used for patient stratification.
Emerging applications of integrative disease modeling in
P4 medicine
With the increasing recognition that integrative systems
modeling will play a major part in all future activities in
P4 medicine, we envision that translational bioinformatics
in general and systems modeling in particular offer more
solutions to current challenges in P4 medicine. In the
following, we provide an outlook on the emerging trend
and future prospects in this area.
Molecular-based classification of diseases and their subtypes
The current classification of diseases is based on anatom-
ical, symptomatic and epidemiological criteria, which does
not take the etiological mechanism into account. This has
led to the problem of misdiagnosis due to the overlap of
symptoms. Consider Parkinson's disease with dementia
and Alzheimer's disease dementia. Since classification of
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their clinical signs, early diagnosis of Parkinson's disease
(PD) is hampered. The extent of clinical overlap between
these two conditions is so much greater than chance
that even some authors propose that AD and PD belong
to a spectrum of neurodegenerative disorders with
common disease mechanism but triggered by different
etiological factors [46]. However, at the molecular
level, these two conditions can be distinguished based
on diagnosis between synucleinopathy from tauopathy.
Thus, integrative disease modeling provides a framework
for incorporation of both conventional reductionism and
non-reductionism approaches and allows for re-definition
of the current nosology [47].
In 2011, National Academy of Sciences committee rec-
ommended NIH to develop a new taxonomy of diseases
based on their underlying molecular and environmental
causes rather than on physical signs and symptoms [48].
The idea is to create a so-called Knowledge Network
information system that integrates molecular data, med-
ical histories and health outcomes of individual patients
(Figure 9).
In 2012, the Innovative Medicines Initiative (IMI) -
Europe's largest public-private partnership aiming to
improve the drug development process - launched a callFigure 9 Architecture of the knowledge network information systemthat addresses the topic of developing an aetiology-based
taxonomy for human diseases. The proposed methodology
for this topic that was submitted by Fraunhofer SCAI and
named AETIONOMY, was selected by IMI consortium
in which we propose a knowledge-based approach to
modeling neurodegenerative disease mechanisms under-
lying Alzheimer's and Parkinson's disease and signa-
ture-based classification of syndromes belonging to these
disorders. The aim of AETIONOMY is to come up with
a new mechanism-based classification system for AD and
PD so that mixed pathologies could be unequivocally
distinguished, new features or classes could be easily
accommodated in the taxonomy, and using this infor-
mation for drug and biomarker discovery could be
facilitated.
Predictive drug re-purposing and modeling polypharmacol-
ogy effect
Low productivity of drug discovery pipelines in recent
years has been largely attributed to insufficient efficacy
of failed drugs. Failure of drugs in phases II and III clin-
ical trials in fact reflects the poor understanding of the
mode of action of such drugs at the molecular level. It is
becoming increasingly evident that approved drugs have
more than one target and this ‘multi-targeting’ nature ofproposed by NAS committee.
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quences in terms of increased efficiency of therapeutic
effect or adverse reactions, respectively. Since approved
drugs have already passed safety tests in clinical trials,
they can be re-used for new therapeutic indications;
however, efficacy still has to be shown for the reposi-
tioned drug. At this point, the re-purposing strategy can
be linked to efficacious targeted therapy for personalized
medicine applications [49]. The recent approval of crizo-
tinib for treatment of non-small cell lung cancer
(NSCLC) that was repositioned from anaplastic large-
cell lymphoma therapy is a good example of linking drug
re-purposing to personalized medicine. The repositioned
drug is accompanied by a diagnostic test for stratifica-
tion of NSCLC patient subsets [50].
Usually, novel disease indications for known drugs
have been discovered by serendipity. It is only recently
that computational and systems approaches have been
employed for inferring and predicting drug repurposing.
These approaches can be grouped into target-based (simi-
lar binding sites) or disease-based (similar mechanisms)
[51]. The rational design of ligands acting on multiple
targets requires that such ligands bear certain molecular
properties. We have recently devised a machine learning
method that successfully classified approved drugs to
NDD and non-NDD drugs based on a set of ten pharma-
cological properties [52]. Integration of drug pharmaco-
logical data and target structural features into tissue- or
organ-specific disease models will support the system-
atic identification of new opportunities (‘re-purposing’)
for existing drugs.
Integrative modeling in support of drug development
decision making
The goal of integrative disease modeling is to provide a
framework for hypothesis generation. Thus, it is ex-
pected that modeling predictions provide many in-
puts into the decision-making process in the
pharmaceutical industry [53]. Since the main reasons
for drug failures in the clinic are efficacy and safety,
target identification and validation are the most im-
portant steps in drug development. Disease-specific
computational models, when enhanced and enriched
with efficacy data, can assist scientists to construct a
more robust rationale in support of the main hy-
pothesis compared to competing hypotheses. Based
on this approach, a likelihood function can be devel-
oped and applied to proof-of-concept decision mak-
ing so that the late-phase drug failures caused by
lack of efficacy could be prevented [54]. Such an in-
tegrative model will summarize the evidence from
multiple data sources that supports competing hy-
potheses on the basis of observed data at any time
point.Comparative modeling of rodent and human
pathobiological mechanisms
High rate of drug failures in general and recent failures
of Alzheimer's therapies in phase III of clinical trials in
particular, despite substantial support from animal stud-
ies, raise the concern whether animal models of chronic
complex diseases reliably inform human conditions.
Several factors including insufficient statistical power,
inadequate internal validity of animal experiments (meth-
odological flaws) and lack of external validity (differences
between animals and humans in the pathophysiology of
the disease) have been reported to be responsible for the
translational failure of apparently promising animal stud-
ies [55].
Reduced external validity of animal studies, includ-
ing insufficient similarity to the human condition
and ignorance of comorbidities, can partially explain
the mechanistic issues behind the poor efficacy of
failed drugs. For example, a systematic study evaluat-
ing the mimicry precision of human inflammation by
mouse models showed that inflammatory responses
in murine models poorly correlated with the human
conditions [56].
In the case of chronic, progressive diseases such as
neurodegenerative disorders, current research has
mainly relied on injury-induced models that do not
recapitulate the progressive, degenerative nature of
the disease in humans. Reasons for this could be at-
tributed to fundamental differences in neural cir-
cuitry between human and rodents as well as
different molecular mechanisms in man from animal
models [57]. The fact that mouse models of human
neurodegenerative diseases have largely failed to pre-
dict the efficacy of clinical trials calls for more rigor-
ous validation of predictions made with the help of
mouse models using alternative strategies [58]. For
instance, in response to the Species Translation
Challenge by sbv IMPROVER [59], we sought to sys-
tematically model and mechanistically compare neu-
roinflammatory pathways between human and mouse
in the context of Alzheimer's disease. Differential
pathway analysis on both models revealed unique
and segregating pathways in human and mouse.
Integrative disease modeling could offer a powerful
approach to increasing the probability of predicting
efficacy of animal data by providing comparative
mouse-human computational models that compute
the extent to which molecular details of animal models
match with the corresponding molecular mechanisms
in human subjects. Ideally, such a comparative study
should take the multiple biological scales from cell and
tissue types to genes, proteins and pathways into ac-
count so that it clearly reveals anatomic and mechanis-
tic differences.
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Integrative in silico disease modeling is emerging as a new
paradigm at the core of translational research, which
prepares the ground for transitioning from descriptive
to mechanistic representation of disease processes. Given
the tremendous potential of integrative disease modeling
in supporting translation of biomarker and drug research
into clinically applicable diagnostic, preventive, prognostic
and therapeutic strategies, it is anticipated that computer-
readable disease models will be an indispensable part of
future efforts in the P4 medicine research area.
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